CMV

The US Food and Drug Administration (FDA) has approved the usage of Roche’s cytomegalovirus (CMV) test for hematopoietic stem cell transplant recipients.

Following the approval, the COBAS AmpliPrep / COBAS TaqMan CMV Test is adopted to monitor CMV treatment in all types of transplant patients in the US.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It is the first in-vitro nucleic acid amplification test compliant to the World Health Organisation (WHO) standards and is used for the quantitative measurement of cytomegalovirus (CMV) DNA.

Roche Molecular Diagnostics head Uwe Oberlaender said: “Cytomegalovirus is the most important viral infection in hematopoietic stem cell transplant patients.

“With this new FDA approval, hematopoietic stem cell transplant clinicians and patients have another tool to help fight CMV.”

CMV is a critical infection commonly affecting transplant patients which can spread through the donor organ, it can also occur due to the reactivation of the virus in transplant recipients already infected with CMV virus.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
“With this new FDA approval, hematopoietic stem cell transplant clinicians and patients have another tool to help fight CMV.”

The CMV test assists the management of solid-organ transplant and hematopoietic stem-cell transplant recipients that have been administered with the anti-CMV therapy.

The serial DNA measurements can be used to test the virological response to antiviral treatment, the result of the test is interpreted within the scope of all relevant clinical and laboratory findings.

The COBAS AmpliPrep / COBAS TaqMan System combines the COBAS AmpliPrep Instrument to facilitate an automated sample preparation and the COBAS TaqMan Analyzer or the smaller COBAS TaqMan 48 Analyzer offers an automated real-time detection of polymerase chain reaction (PCR).

However the COBAS AmpliPrep / COBAS TaqMan CMV Test cannot be used as a screening test to detect the presence of CMV DNA in blood or blood products.

Image: Histopathology of lung displays CMV infection. Photo: courtesy of CDC/Dr. Edwin P. Ewing, Jr.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact